The FDA has currently approved two methylation-based diagnostic biomarkers for CRC: SEPT9 and the combination of bone morphogenetic protein 3 (BMP3) and N-Myc downstream-regulated gene 4 (NDRG4) [77,80]. The gene discussed is BMP3; the disease is colorectal carcinoma.